Physician profile
Trisha B Nashed
NPI 1124084041
$1,907.98
in general payments reported to CMS, 2019-2025
18 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $41.41 · 2021: $18.52 · 2022: $347 · 2023: $602 · 2024: $325 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $403.56 | 2022-2024 | Corevalve Evolut R |
| Pfizer INC. | $292.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $204.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $203.92 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $141.80 | 2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.65 | 2021-2023 | Jardiance |
| Boston Scientific Corporation | $114.51 | 2022-2025 | Watchman Access System |
| Kiniksa Pharmaceuticals, Ltd. | $91.91 | 2022 | |
| Novo Nordisk INC | $60.71 | 2023-2024 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.05 | 2019-2024 | Lifevest |
| Amgen INC. | $42.17 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $36.98 | 2023 | |
| Amarin Pharma, INC. | $32.91 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $31.29 | 2025 | Assure Wcd |
| Celonova Biosciences, INC. | $13.95 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $13.48 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.29 | 2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Nashed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.